You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 15, 2025

CLINICAL TRIALS PROFILE FOR OSPEMIFENE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ospemifene

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00276094 ↗ A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women Completed Hormos Medical Phase 3 2006-01-01 The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
NCT00276094 ↗ A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women Completed QuatRx Pharmaceuticals Phase 3 2006-01-01 The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
NCT00276094 ↗ A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women Completed Shionogi Phase 3 2006-01-01 The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ospemifene

Condition Name

Condition Name for Ospemifene
Intervention Trials
Vaginal Diseases 6
Atrophy 6
Sexual Dysfunction, Physiological 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ospemifene
Intervention Trials
Atrophy 7
Vaginal Diseases 6
Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ospemifene

Trials by Country

Trials by Country for Ospemifene
Location Trials
United States 31
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ospemifene
Location Trials
Georgia 2
California 2
Texas 1
Tennessee 1
South Dakota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ospemifene

Clinical Trial Phase

Clinical Trial Phase for Ospemifene
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ospemifene
Clinical Trial Phase Trials
Completed 8
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ospemifene

Sponsor Name

Sponsor Name for Ospemifene
Sponsor Trials
Shionogi 7
QuatRx Pharmaceuticals 6
Hormos Medical 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ospemifene
Sponsor Trials
Industry 17
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Osphena (Ospemifene): Clinical Trials, Safety, Efficacy, and Market Analysis

Introduction

Osphena, containing the active ingredient ospemifene, is a selective estrogen receptor modulator (SERM) designed to treat moderate to severe vaginal dryness and dyspareunia associated with vulvovaginal atrophy (VVA) in postmenopausal women. Here, we delve into the clinical trials, safety profile, efficacy, and market projections for Osphena.

Clinical Trials Overview

Osphena's safety and efficacy have been extensively evaluated through multiple clinical trials.

  • Phase 2/3 Trials: Ten phase 2/3 trials involving 2,209 postmenopausal women with VVA were conducted. These trials included doses ranging from 5 to 90 mg per day, with treatment durations from 6 weeks to 15 months. Notably, 847 women were studied for up to 52 weeks[1][5].

  • Long-term Safety: A 52-week long-term safety trial was conducted, which enrolled 426 healthy postmenopausal women. This trial assessed the safety profile over an extended period, showing results similar to the shorter-term trials[5].

Safety Profile

Endometrial Safety

Osphena's clinical trials were unique in that they did not require the addition of a progestin, even in women with an intact uterus. However, the drug carries a Boxed Warning regarding endometrial cancer and cardiovascular disorders. Women with undiagnosed persistent or recurring abnormal genital bleeding should undergo diagnostic measures to rule out malignancy[1].

Breast Safety

Clinical studies showed no clinically significant mammographic changes in Osphena-treated patients. There was a decrease in abnormal breast palpation findings and a low rate of breast-related treatment-related adverse events. Importantly, no cases of breast cancer were reported in the Osphena group, although the drug has not been adequately studied in women with known or suspected breast cancer[1].

Cardiovascular Safety

Less than 1% of patients experienced treatment-related cardiovascular events in the clinical trials. The incidence rates of hemorrhagic stroke, thromboembolic stroke, and deep vein thrombosis were monitored, with some cases reported but at low frequencies[1][5].

Efficacy

Vaginal Tissue Improvements

Osphena significantly improved vaginal tissue health by increasing the proportion of superficial cells and decreasing the proportion of parabasal cells. These changes were statistically significant across multiple trials (p < 0.0001)[4][5].

Vaginal pH Reduction

The drug reduced vaginal pH significantly by Week 12 in all three clinical trials, which is a key indicator of improved vaginal health (p < 0.0001)[4][5].

Symptom Relief

Osphena relieved symptoms of moderate to severe vaginal dryness and dyspareunia. Patients reported significant improvements in these symptoms by Week 12, with statistically significant differences compared to the placebo group (p < 0.0001 for vaginal dryness and p = 0.0012 for dyspareunia)[4][5].

Common Adverse Reactions

The most frequently reported adverse drug reactions included hot flushes, vaginal discharge, muscle spasm, and hyperhidrosis. Less common reactions included breast pain/tenderness, endometrial hypertrophy, acne, pruritus, rash, depression, and insomnia[5].

Market Analysis and Projections

Market Size and Growth

The U.S. vaginal atrophy treatment market, which includes Osphena, was valued at $1.15 billion in 2023 and is projected to grow to $1.63 billion by 2032. The oral segment, where Osphena is categorized, is expected to witness lucrative growth due to its non-hormonal nature and fewer side effects compared to hormonal treatments[2].

Distribution Channels

The market is segmented into retail stores & pharmacies, hospital pharmacies, and online channels. The easy accessibility and availability of Osphena in these channels contribute to its market dominance[2].

Competitive Advantage

Osphena, being the only FDA-approved non-hormonal oral drug for VVA symptoms, has a significant competitive advantage. Its safety profile, including reduced risks of cardiovascular events and cancers, further enhances its market position[2].

Key Takeaways

  • Extensive Clinical Trials: Osphena has been evaluated in ten phase 2/3 trials and a 52-week long-term safety trial.
  • Safety Profile: While Osphena has a favorable safety profile, it carries a Boxed Warning for endometrial cancer and cardiovascular disorders.
  • Efficacy: The drug significantly improves vaginal tissue health, reduces vaginal pH, and relieves symptoms of vaginal dryness and dyspareunia.
  • Market Growth: The U.S. vaginal atrophy treatment market is projected to grow, with the oral segment, including Osphena, expected to see significant growth.
  • Competitive Advantage: Osphena's non-hormonal nature and favorable safety profile make it a preferred option in the market.

FAQs

Q: What is Osphena used for?

A: Osphena is used to treat moderate to severe vaginal dryness and dyspareunia associated with vulvovaginal atrophy (VVA) in postmenopausal women.

Q: Is Osphena a hormonal treatment?

A: No, Osphena is a non-hormonal treatment. It is a selective estrogen receptor modulator (SERM) that acts on estrogen receptors without the use of hormones.

Q: What are the common side effects of Osphena?

A: Common side effects include hot flushes, vaginal discharge, muscle spasm, and hyperhidrosis. Less common reactions include breast pain/tenderness, endometrial hypertrophy, and others.

Q: Can Osphena be used in women with breast cancer?

A: No, Osphena has not been adequately studied in women with known or suspected breast cancer and should not be used in these cases.

Q: How does Osphena improve vaginal health?

A: Osphena improves vaginal health by increasing the proportion of superficial cells, decreasing the proportion of parabasal cells, and reducing vaginal pH, all of which are statistically significant improvements.

Sources

  1. Osphena Safety Profile: Osphena® safety and efficacy have been confirmed by multiple clinical trials, https://hcp.osphena.com/safety
  2. U.S. Vaginal Atrophy Treatment Market: U.S. Vaginal Atrophy Treatment Market Size, Share [2024-2032], https://www.fortunebusinessinsights.com/u-s-vaginal-atrophy-treatment-market-109727
  3. Shionogi Financial Results: 1st Half of Fiscal 2021 Financial Results - Shionogi Inc., https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/presentation/2021/e_20211101_final.pdf
  4. Osphena Efficacy: Patients reported significant improvements in moderate to severe vaginal dryness and dyspareunia, https://hcp.osphena.com/efficacy
  5. Summary Basis of Decision for Osphena: Osphena is an oral, non-hormonal option for the treatment of dyspareunia and/or vaginal dryness, https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00564
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.